Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zevra Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $630.9 Mil.
Zevra Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics EV-to-EBIT Related Terms
Zevra Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zevra Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's EV-to-EBIT falls into.
Zevra Therapeutics's current Enterprise Value is $467.0 Mil.
Zevra Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (ZVRA) has a EV-to-EBIT of 6.23 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zevra Therapeutics and its competitors. According to the industry distribution chart, Zevra Therapeutics ranks #123 out of 365 companies in the Biotechnology industry, placing it in the top 33.7%.
Is Zevra Therapeutics' EV-to-EBIT too high?
Zevra Therapeutics' current EV-to-EBIT is 6.23. The Biotechnology industry median EV-to-EBIT is 15.95. Zevra Therapeutics' value of 6.23 is 60.9% below this industry median. Based on the distribution chart, Zevra Therapeutics ranks #123 out of 365 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zevra Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' EV-to-EBIT compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #123 out of 365 companies for EV-to-EBIT. This puts Zevra Therapeutics in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Zevra Therapeutics' value of 6.23 is 60.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current EV-to-EBIT of 6.23 is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current EV-to-EBIT is 6.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $21.13, compared to a current price of $11.57 — trading 45.2% below its estimated fair value. The current EV-to-EBIT is 6.23 and 60.9% below the Biotechnology industry median of 15.95. Zevra Therapeutics' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current EV-to-EBIT is 6.23 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $11.57 is trading 45.2% below its estimated GF Value™ of $21.13.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
EV-to-EBIT: 6.23
GF Value™: $21.13 vs. price of $11.57 (45.2% below fair value)
Industry Position: 60.9% below the Biotechnology median (#123 of 365)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
68GF Score
Get the complete analysis for ZVRA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
